Close Menu

NEW YORK (GenomeWeb) – Guardant Health said today that it has priced its previously announced underwritten public offering of 4.5 million shares of common stock at $71.00 per share.

The company has also granted underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price. Guardant expects resulting gross proceeds of $319.5 million, excluding any exercise of the underwriters' additional share purchase option.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.